Introduction

On April 22, 2024, the U.S. Supreme Court denied Vanda Pharmaceuticals’ petition for certiorari in its patent infringement dispute against Teva Pharmaceutical Industries, Ltd. and Apotex Corp., closing Case No. 23-768 after just 101 days. The case centered on four patents protecting Vanda’s branded sleep disorder drug Hetlioz® (tasimelteon), a melatonin receptor agonist approved for non-24-hour sleep-wake disorder.

The Supreme Court’s refusal to hear the case—without comment, as is standard in petition denials—leaves intact lower court rulings that had gone against Vanda’s position, effectively clearing a path for generic competitors in the tasimelteon market. For pharmaceutical patent holders and IP professionals navigating Hatch-Waxman litigation, this outcome offers a critical data point: even a robust multi-patent portfolio covering a branded pharmaceutical product is not insulated from challenge. The denial underscores growing judicial scrutiny of pharmaceutical method-of-treatment and formulation patents in an era of increasing generic competition.

Case Overview

The Parties

The Patents at Issue

Four patents formed the basis of Vanda’s infringement claims. These patents collectively protect methods of treating Non-24 using tasimelteon, dosing regimens, and related pharmaceutical applications. The inclusion of a reissue patent (USRE046604E) is particularly significant, as it signals prior USPTO proceedings in which Vanda refined its claim scope—a strategic prosecution decision that may have influenced the litigation outcome.

• • US10376487B2 (Application No. US14/511669)
• • US10149829B2 (Application No. US15/382526)
• • US9730910B2 (Application No. US14/510321)
• • USRE046604E (Application No. US15/051978) — notably a reissue patent

Litigation Timeline & Procedural History

The case reached the U.S. Supreme Court as a judicial review proceeding, meaning Vanda sought certiorari following adverse rulings in lower courts—most likely originating in district court Hatch-Waxman patent infringement litigation and proceeding through the U.S. Court of Appeals for the Federal Circuit, the specialized appellate court with jurisdiction over patent matters.

The 101-day duration from filing to closure reflects the Supreme Court’s standard petition review timeline. The Court receives thousands of certiorari petitions annually, granting fewer than 2%. The efficiency of the closure—without briefing on the merits—indicates the petition was denied at conference, consistent with the Court’s typical handling of pharmaceutical patent cases unless a circuit split or constitutional question is presented.

Legal Representation

• • Plaintiff (Vanda): Paul Whitfield Hughes of **McDermott Will & Emery LLP**
• • Defendants (Teva/Apotex): John Christopher Rozendaal of **Sterne, Kessler, Goldstein & Fox PLLC**

Both firms are nationally recognized for pharmaceutical patent and ANDA litigation, lending significant strategic weight to the proceedings at every level.

The Verdict & Legal Analysis

Outcome

The Supreme Court denied Vanda’s petition for certiorari on April 22, 2024. No damages were assessed at this stage, as a certiorari denial is a procedural outcome rather than a merits ruling. The denial effectively terminates Vanda’s appellate pursuit, leaving the lower court’s judgment—adverse to Vanda—as the operative final decision. No injunctive relief was granted through this proceeding.

Verdict Cause Analysis

The underlying cause of action was patent infringement, brought under the Hatch-Waxman Act’s artificial infringement provisions (35 U.S.C. § 271(e)(2)). Vanda’s four-patent assertion against Teva and Apotex followed the defendants’ ANDA filings, which included Paragraph IV certifications asserting that Vanda’s patents were invalid, unenforceable, or would not be infringed by the generic product.

The specific legal reasoning applied by lower courts is not disclosed in the available case data. However, several factors commonly determine outcomes in tasimelteon-adjacent Hatch-Waxman cases, including:

• • Patent eligibility under 35 U.S.C. § 101: Method-of-treatment claims covering naturally occurring biological phenomena have faced significant § 101 challenges post-*Mayo Collaborative Services v. Prometheus Laboratories* (2012).
• • Claim construction: The breadth and specificity of method claims in pharmaceutical patents are frequently contested, with narrow constructions often defeating infringement.
• • Obviousness under § 103: Generic challengers routinely assert prior art combinations against pharmaceutical dosing and treatment claims.

The inclusion of USRE046604E, a reissue patent, introduces additional vulnerability, as reissue patents may face recapture rule challenges if broadened claims are asserted beyond the original patent’s scope.

Legal Significance

A certiorari denial carries no precedential value as a legal ruling on the merits. The Supreme Court’s silence does not validate or invalidate the Federal Circuit’s decision. However, the denial is practically significant: it signals that the Court did not find the legal questions presented sufficiently novel, conflicted, or nationally important to warrant review.

For pharmaceutical patent litigation broadly, this outcome reinforces the durability of Federal Circuit decisions in Hatch-Waxman cases absent extraordinary circumstances.

Strategic Takeaways

For Patent Holders:

• • Multi-patent portfolio strategies (four patents here) provide layered protection but do not guarantee litigation success if underlying claim validity is compromised.
• • Reissue patents, while tactically useful for claim refinement, introduce prosecution history estoppel risks that defendants can exploit.
• • Early assessment of § 101 exposure for method-of-treatment claims is essential before litigation investment.

For Accused Infringers (Generic Manufacturers):

• • Paragraph IV certification remains a powerful tool for challenging pharmaceutical patent portfolios.
• • Coordinated multi-defendant challenges (Teva + Apotex jointly) can pool resources and present stronger invalidity records.

For R&D and Freedom-to-Operate (FTO) Teams:

• • Drug developers should conduct FTO analysis inclusive of reissue patents and continuation applications, as these may extend protection timelines unexpectedly.
• • Monitor ANDA litigation outcomes as leading indicators of market entry timelines for biosimilar and generic competition planning.

Industry & Competitive Implications

The Supreme Court’s denial has immediate commercial consequences for Vanda Pharmaceuticals. With the lower court’s ruling intact and certiorari exhausted, generic tasimelteon entry becomes substantially more viable for Teva and Apotex, subject to any remaining regulatory or 30-month stay considerations under Hatch-Waxman.

For the broader pharmaceutical industry, this case reflects a continuing trend: branded pharmaceutical companies face increasing difficulty sustaining multi-patent exclusivity barriers in the post-*Mayo/Alice* era, particularly where method-of-treatment claims are involved. The Federal Circuit has shown willingness to invalidate or narrowly construe pharmaceutical method patents, and the Supreme Court’s consistent non-intervention in these cases reinforces Federal Circuit authority as the practical final word in patent disputes.

From a licensing perspective, the outcome reduces Vanda’s leverage in any prospective licensing negotiations with generic manufacturers for tasimelteon. Companies holding similar method-of-treatment patent portfolios in CNS, sleep medicine, and related therapeutic areas should treat this case as a prompt to re-evaluate their patent prosecution and litigation strategies.